Heptares Therapeutics

www.heptares.com

BioPark
Broadwater Road
Welwyn Garden City
Hertfordshire
AL7 3AX
United Kingdom

+44 1707 358628

Activities

Research & Development | Pharmaceutical

Related Companies

Related Content

Heptares enters drug collaboration with Imperial
Heptares enters drug collaboration with Imperial
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Heptares enters research and drug discovery collaboration
Heptares enters research and drug discovery collaboration
New programme focused on GPCR target implicated in brain cancer 
New programme focused on GPCR target implicated in brain cancer 
Heptares plans relocation to Cambridge, UK
Heptares plans relocation to Cambridge, UK
John Daly Lecture Award for Heptares’ co-founder
John Daly Lecture Award for Heptares’ co-founder
New insights to advance drug discovery in pain, cancer and inflammation
New insights to advance drug discovery in pain, cancer and inflammation
Heptares Therapeutics enters agreement with Daichi Sankyo
Heptares Therapeutics enters agreement with Daichi Sankyo
New programme focused on apelin receptor in cardiovascular diseases
New programme focused on apelin receptor in cardiovascular diseases
Heptares scientists solve structure of CCR9 chemokine receptor offering unique opportunity to apply structure-based design across chemokine receptor family
Heptares scientists solve structure of CCR9 chemokine receptor offering unique opportunity to apply structure-based design across chemokine receptor family
Heptares and Jitsubo to develop novel GPCR-targeting peptide candidates for severe gastrointestinal disorders
Heptares and Jitsubo to develop novel GPCR-targeting peptide candidates for severe gastrointestinal disorders
Heptares and leadXpro to collaborate on GPCR drug discovery
Heptares and leadXpro to collaborate on GPCR drug discovery
Heptares and Kymab enter into novel antibody therapeutics collaboration
Heptares and Kymab enter into novel antibody therapeutics collaboration
Allergan and Heptares enter global R&D licensing agreement potentially worth US$3.35bn
Allergan and Heptares enter global R&D licensing agreement potentially worth US$3.35bn
Heptares joins consortium applying cryo-electron microscopy to structure-based drug discovery
Heptares joins consortium applying cryo-electron microscopy to structure-based drug discovery